Pay in 4 interest-free payments of $5.22 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Zepbound (tirzepatide) is a dual GLP-1/GIP receptor agonist that provides more significant weight loss results (up to 20%) than single GLP-1 receptor agonists such as semaglutide (Wegovy) and liraglutide
Rapid fat mobilization during weight loss, and dehydration from reduced appetite, can temporarily affect liver enzymes
However, if used in combination with other diabetes medications that can lower blood sugar (such as insulin or sulfonylureas), there can be an increased risk
The Wegovy dosage schedule will help you to reach the maximum dosage gradually to help limit the risk of side effects and give your body time to adjust to the medication
In the SURMOUNT-2 trial, tirzepatide 15 mg achieved mean weight reductions of 21% body weight, compared to semaglutide 2.4 mg, which produced approximately 17% reductions in the STEP trials
